Ultimovacs ASA is a Norwegian biotechnology company specializing in developing immunotherapies for treating cancer. The company's values and corporate philosophy revolve around innovation, dedication to patient care, and a commitment to advancing cancer treatments. Ultimovacs ASA strives to make a difference in the lives of cancer patients by utilizing cutting-edge science and technology to create effective therapies. By focusing on continuous research and collaboration, Ultimovacs ASA aims to revolutionize cancer treatment and improve patient outcomes. With a strong emphasis on scientific rigor and a patient-centric approach, Ultimovacs ASA stands as a leader in the field of cancer immunotherapies.

Ultimovacs ASA is primarily present in Norway, where it is headquartered.

Ultimovacs ASA has achieved several significant milestones. The company successfully conducted a Phase I trial for their universal cancer vaccine, UV1, demonstrating its safety and immune activation properties. They also initiated a Phase II clinical trial to evaluate the vaccine's efficacy in patients with malignant melanoma, prostate cancer, or non-small cell lung cancer. Ultimovacs ASA further secured funding through a successful IPO, strengthening their financial position and enabling further research and development activities. These milestones highlight Ultimovacs ASA's commitment to advancing innovative immunotherapies and their potential to transform cancer treatment.

Ultimovacs ASA is a Norwegian biotechnology company that specializes in developing immunotherapies to treat cancer. Established in 2011, Ultimovacs focuses on enhancing the body's immune system to combat tumors effectively. The company's innovative technologies revolve around therapeutic cancer vaccines and immune checkpoint inhibitors. Ultimovacs has conducted extensive research and clinical trials to advance its cutting-edge immunotherapy treatments. Its prominent portfolio includes UV1, a peptide-based vaccine with vast potential for multiple cancer types. With a dedicated team of experts and strong collaborations, Ultimovacs ASA aims to make significant strides in the field of cancer treatment and improve patient outcomes.

The main competitors of Ultimovacs ASA in the market include companies such as Bristol-Myers Squibb, Merck & Co., Roche Holding AG, AstraZeneca PLC, and Novartis AG.

Ultimovacs ASA is primarily active in the biotechnology and healthcare industries.

The business model of Ultimovacs ASA focuses on developing novel immunotherapies to treat various types of cancers. By leveraging its proprietary technology platform, known as Universal Immunotherapy, the company aims to activate and enhance the body's immune system to effectively fight against cancer cells. Ultimovacs ASA primarily focuses on the development of therapeutic cancer vaccines, which are designed to stimulate the patient's immune system to recognize and target cancer-specific antigens. Through rigorous research and clinical trials, Ultimovacs ASA aims to bring forth innovative solutions in the field of cancer immunotherapy, ultimately improving patient outcomes and quality of life.

Ultimovacs A P/E suhe on −1,00.

Ultimovacs A KUV on 0.

AlleAktien kvaliteediskoor ettevõttele Ultimovacs A on 2/10.

Praegu ei saa Ultimovacs A käivet arvutada.

oodatud Ultimovacs A kasum on −84,20 mln. NOK.

Ultimovacs ASA is a biopharmaceutical company focused on the development of cancer therapies. The company was founded in 2011 and is based in Oslo, Norway. Ultimovacs ASA's business model is based on the research and development of cancer therapies that rely on stimulating the body's own immune system. Ultimovacs ASA has several divisions focused on the research and development of cancer therapies. One important division is immunotherapy, which stimulates the body's immune system to fight cancer cells. Ultimovacs ASA works closely with universities, research institutions, and other companies to leverage the latest developments and technologies in this field. The company also offers diagnostic tests that can help improve the effectiveness of cancer therapies. These tests are based on the analysis of tumor tissue samples and aim to personalize cancer treatment. Ultimovacs ASA has several products in its pipeline, including immunotherapies for treating various types of cancer such as lung cancer, melanoma, and prostate cancer. These therapies are based on stimulating the body's own immune system to fight cancer cells. The company is also working on the development of combination therapies that combine different immunotherapies and other cancer treatments to achieve higher effectiveness. Ultimovacs ASA works closely with regulatory authorities to obtain approval and bring its products to market. The company also ensures that its products are manufactured in accordance with international quality standards. Ultimovacs ASA's business model is based on the development and marketing of cancer therapies that stimulate the body's own immune system to fight cancer cells. The company works closely with other companies and research institutions to leverage the latest developments in this field. It also offers diagnostic tests that can help improve the effectiveness of cancer therapies. Ultimovacs ASA works closely with regulatory authorities to obtain approval and bring its products to market. The company aims for broad distribution of its products to help as many patients with different types of cancer as possible.

Ultimovacs A maksab dividendi 0 NOK, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Ultimovacs A jaoks arvutada või ettevõte ei maksa dividende välja.

Ultimovacs A ISIN on NO0010851603.

Ultimovacs A WKN on A2PKSD.

Ultimovacs A tähis on ULTI.OL.

Viimase 12 kuu jooksul maksis Ultimovacs A dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Ultimovacs A tõenäoliselt dividendi summas 0 NOK.

Ultimovacs A praegune dividenditootlus on .

Ultimovacs A maksab kvartaalset dividendi. See makstakse välja kuudel .

Ultimovacs A maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 NOK. See vastab dividenditootlusele 0 %.

Ultimovacs A on liigitatud sektorisse 'Tervis'.

Viimase Ultimovacs A dividendide saamiseks 13.9.2024 suuruses 0 NOK pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 13.9.2024.

Viimane dividendimakse toimus 13.9.2024.

Aastal 2023 maksis Ultimovacs A 0 NOK dividende.

Ultimovacs A dividendid makstakse välja NOK.